About the study
AERIFY-3 was an exploratory Phase 2a study of how itepekimab, an investigational anti-IL-33 antibody, works on airway inflammation in COPD. Participants received 12 weeks of treatment, and researchers studied samples from the airways and nose to understand the medicine's effects in former and current smokers.
Who took part
The study enrolled people who:
- Were 40 to 70 years old
- Had COPD with chronic bronchitis symptoms and a smoking history of at least 10 pack-years
Status at Veritas
This study has been completed. It is no longer enrolling, and it is listed here as part of Veritas Clinical Research's track record as a research site.
Learn more
The full study record, including all eligibility criteria and outcome measures, is on ClinicalTrials.gov (NCT05326412).